The DNA loop release factor WAPL suppresses Epstein-Barr virus latent membrane protein expression to maintain the highly restricted latency I program
PLOS Pathogens · 2024
DOI: 10.1371/journal.ppat.1012525 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2024. Verfasst von Laura A Murray-Nerger und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America. Hauptthemen laut MEDLINE: Herpesvirus 4, Human, Virus Latency, Viral Matrix Proteins, Gene Expression Regulation, Viral. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Epstein-Barr virus (EBV) uses latency programs to colonize the memory B-cell reservoir, and each program is associated with human malignancies. However, knowledge remains incomplete of epigenetic mechanisms that maintain the highly restricted latency I program, present in memory and Burkitt lymphoma cells, in which EBNA1 is the only EBV-encoded protein expressed. Given increasing appreciation that higher order chromatin architecture is an important determinant of viral and host gene expression, we investigated roles of Wings Apart-Like Protein Homolog (WAPL), a host factor that unloads cohesin to control DNA loop size and that was discovered as an EBNA2-associated protein. WAPL knockout (KO) in Burkitt cells de-repressed LMP1 and LMP2A expression, but not other EBV oncogenes, to yield a viral program reminiscent of EBV latency II, which is rarely observed in B-cells. WAPL KO also increased LMP1/2A levels in latency III lymphoblastoid cells. WAPL KO altered EBV genome architecture, triggering formation of DNA loops between the LMP promoter region and the EBV origins of lytic replication ( oriLyt ). Hi-C analysis further demonstrated that WAPL KO reprogrammed EBV genomic DNA looping. LMP1 and LMP2A de-repression correlated with decreased histone repressive marks at their promoters. We propose that EBV coopts WAPL to negatively regulate latent membrane protein expression to maintain Burkitt latency I.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
- Department of Microbiology, Harvard Medical School, Boston, Massachusetts, United States of America.
- Harvard Program in Virology, Boston, Massachusetts, United States of America.
- Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America.
- The Wistar Institute, Philadelphia, Pennsylvania, United States of America.
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy.
ORCID-Profile: Benjamin E Gewurz
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Murray-Nerger, L. A., Maestri, D., Liu, X., Li, Z., Auld, N. R., Tempera, I., Teng, M., & Gewurz, B. E. (2024). The DNA loop release factor WAPL suppresses Epstein-Barr virus latent membrane protein expression to maintain the highly restricted latency I program. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012525
Vancouver
Murray-Nerger LA, Maestri D, Liu X, Li Z, Auld NR, Tempera I, et al. The DNA loop release factor WAPL suppresses Epstein-Barr virus latent membrane protein expression to maintain the highly restricted latency I program. PLOS Pathogens. 2024. doi:10.1371/journal.ppat.1012525
BibTeX
@article{MurrayNerger2024,
author = {Murray-Nerger, Laura A and Maestri, Davide and Liu, Xiang and Li, Zhixuan and Auld, Nina R and Tempera, Italo and Teng, Mingxiang and Gewurz, Benjamin E},
title = {The DNA loop release factor WAPL suppresses Epstein-Barr virus latent membrane protein expression to maintain the highly restricted latency I program},
journal = {PLOS Pathogens},
year = {2024},
doi = {10.1371/journal.ppat.1012525}
}
EUVIMED